JP2015532307A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015532307A5 JP2015532307A5 JP2015536187A JP2015536187A JP2015532307A5 JP 2015532307 A5 JP2015532307 A5 JP 2015532307A5 JP 2015536187 A JP2015536187 A JP 2015536187A JP 2015536187 A JP2015536187 A JP 2015536187A JP 2015532307 A5 JP2015532307 A5 JP 2015532307A5
- Authority
- JP
- Japan
- Prior art keywords
- factor vii
- polypeptide
- polypeptide according
- polymer
- asn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 23
- 102100023804 Coagulation factor VII Human genes 0.000 claims 18
- 108010023321 Factor VII Proteins 0.000 claims 18
- 229940012413 factor vii Drugs 0.000 claims 18
- 229920001184 polypeptide Polymers 0.000 claims 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims 18
- 229920000642 polymer Polymers 0.000 claims 7
- 238000006467 substitution reaction Methods 0.000 claims 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 2
- 108010088751 Albumins Proteins 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229920002674 hyaluronan Polymers 0.000 claims 2
- 229960003160 hyaluronic acid Drugs 0.000 claims 2
- 102100022641 Coagulation factor IX Human genes 0.000 claims 1
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- 201000003542 Factor VIII deficiency Diseases 0.000 claims 1
- 208000009292 Hemophilia A Diseases 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 102000004338 Transferrin Human genes 0.000 claims 1
- 108090000901 Transferrin Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 208000034158 bleeding Diseases 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 208000009429 hemophilia B Diseases 0.000 claims 1
- 208000031169 hemorrhagic disease Diseases 0.000 claims 1
- 230000002439 hemostatic effect Effects 0.000 claims 1
- 229940099816 human factor vii Drugs 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 claims 1
- 229950004354 phosphorylcholine Drugs 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 claims 1
Claims (15)
- ヒト第VII因子のアミノ酸配列(配列番号1)と比べて2つ以上の置換を含む第VII因子(a)ポリペプチドであって、
置換の少なくとも1つが、T293がLys(K)、Tyr(Y)、Arg(R)もしくはPhe(F)により置換され、Q176がLys(K)、Arg(R)、Asn(N)により置換され、および/またはQ286がAsn(N)により置換されている所にあり、
置換の少なくとも1つが、M298がGln(Q)、Lys(K)、Arg(R)、Asn(N)、Gly(G)、Pro(P)、Ala(A)、Val(V)、Leu(L)、Ile(I)、Phe(F)、Trp(W)、Tyr(Y)、Asp(D)、Glu(E)、His(H)、Cys(C)、Ser(S)、またはThr(T)により置換されている所にある、
第VII因子(a)ポリペプチド。 - T293がLys(K)、Tyr(Y)、Arg(R)、またはPhe(F)により置換されている、請求項1に記載の第VII因子(a)ポリペプチド。
- Q176がLys(K)、Arg(R)、またはAsn(N)により置換されている、請求項1に記載の第VII因子(a)ポリペプチド。
- Q286がAsn(N)により置換されている、請求項1に記載の第VII因子(a)ポリペプチド。
- M298がQにより置換されている、請求項1から4のいずれか一項に記載の第VII因子(a)ポリペプチド。
- ポリペプチドが、以下の置換の群T293K/M298Q、T293Y/M298Q、T293R/M298Q、T293F/M298Q、Q176K/M298Q、Q176R/M298Q、Q176N/M298Q、Q286N/M298Q、T293Y/V158D/E296V/M298Q、T293R/V158D/E296V/M298Q、T293K/V158D/E296V/M298Q、Q176K/V158D/E296V/M298Q、またはQ176R/V158D/E296V/M298Qの1つを有する、請求項1に記載の第VII因子(a)ポリペプチド。
- 第VII因子(a)ポリペプチドが少なくとも1つの半減期延長部分とカップリングされている、請求項1から6のいずれか一項に記載の第VII因子(a)ポリペプチド。
- 半減期延長部分が、生体適合性脂肪酸およびこの誘導体、ヒドロキシアルキルデンプン(HAS)、ポリエチレングリコール(PEG)、Poly(Glyx-Sery)n(HAP)、ヒアルロン酸(HA)、ヘパロサンポリマー(HEP)、ホスホリルコリンベースのポリマー(PCポリマー)、フレキシマー、デキストラン、ポリシアル酸(PSA)、Fcドメイン、トランスフェリン、アルブミン、エラスチン様(ELP)ペプチド、XTENポリマー、PASポリマー、PAポリマー、アルブミン結合ペプチド、CTPペプチド、およびFcRn結合ペプチドから選択される、請求項7に記載の第VII因子(a)ポリペプチド。
- 半減期延長部分がヘパロサンポリマーである、請求項8に記載の第VII因子(a)ポリペプチド。
- 第VII因子(a)ポリペプチドが追加の変異R396C、Q250C、または407Cを有する、請求項7から8のいずれか一項に記載の第VII因子(a)ポリペプチド。
- 請求項1から10のいずれか一項に記載の第VII因子(a)ポリペプチドを産生する方法。
- 請求項1から10のいずれか一項に記載の第VII因子(a)ポリペプチドを含む医薬組成物。
- 対象における出血障害もしくは出血エピソードの治療、または正常な止血系の増強のための方法であって、請求項1から10のいずれか一項に記載の第VII因子(a)ポリペプチドの治療的または予防的に有効な量を、これを必要とする対象に投与する工程を含む、方法。
- 医薬品として使用するための、請求項1から10のいずれか一項に記載の第VII因子(a)ポリペプチド。
- 血友病AまたはBの治療において医薬品として使用するための、請求項14に記載の第VII因子(a)ポリペプチド。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12188473.8 | 2012-10-15 | ||
| EP12188473 | 2012-10-15 | ||
| US201261715920P | 2012-10-19 | 2012-10-19 | |
| US61/715,920 | 2012-10-19 | ||
| PCT/EP2013/071510 WO2014060401A1 (en) | 2012-10-15 | 2013-10-15 | Coagulation factor vii polypeptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015532307A JP2015532307A (ja) | 2015-11-09 |
| JP2015532307A5 true JP2015532307A5 (ja) | 2016-12-01 |
Family
ID=47022566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015536187A Withdrawn JP2015532307A (ja) | 2012-10-15 | 2013-10-15 | 凝固因子ｖｉｉポリペプチド |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20150307865A1 (ja) |
| EP (1) | EP2906693A1 (ja) |
| JP (1) | JP2015532307A (ja) |
| CN (1) | CN104704118A (ja) |
| WO (1) | WO2014060401A1 (ja) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI538916B (zh) | 2008-04-11 | 2016-06-21 | 介控生化科技公司 | 經修飾的因子vii多肽和其用途 |
| WO2011075185A1 (en) | 2009-12-18 | 2011-06-23 | Oligasis | Targeted drug phosphorylcholine polymer conjugates |
| EP2906247A1 (en) | 2012-10-15 | 2015-08-19 | Novo Nordisk Health Care AG | Factor vii conjugates |
| DK3041513T3 (da) | 2013-09-08 | 2020-10-26 | Kodiak Sciences Inc | Zwitterioniske faktor viii-polymerkonjugater |
| US9371370B2 (en) | 2013-10-15 | 2016-06-21 | Novo Nordisk Healthcare Ag | Coagulation factor VII polypeptides |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| KR20210013299A (ko) | 2014-10-17 | 2021-02-03 | 코디악 사이언시스 인코포레이티드 | 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트 |
| EP3397276A4 (en) | 2015-12-30 | 2019-12-18 | Kodiak Sciences Inc. | ANTIBODIES AND CONJUGATES THEREOF |
| CA3030533A1 (en) * | 2016-07-11 | 2018-01-18 | Oren HERSHKOVITZ | Long-acting coagulation factor vii and methods of producing same |
| CN106279436B (zh) * | 2016-08-19 | 2017-10-31 | 安源医药科技（上海）有限公司 | 活化的人凝血因子vii融合蛋白及其制备方法与用途 |
| CN107102125B (zh) * | 2017-04-17 | 2019-07-09 | 中国科学院苏州生物医学工程技术研究所 | 血栓弹力图仪的校准方法 |
| AU2019227997A1 (en) | 2018-03-02 | 2020-09-24 | Kodiak Sciences Inc. | IL-6 antibodies and fusion constructs and conjugates thereof |
| CN110218258A (zh) * | 2019-06-12 | 2019-09-10 | 福建农林大学 | 融合三肽囊素的克隆表达及应用 |
| EP3833381B1 (en) | 2019-08-15 | 2022-08-03 | Catalyst Biosciences, Inc. | Modified factor vii polypeptides for subcutaneous administration |
| WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4203570A (en) | 1978-08-23 | 1980-05-20 | The Western States Machine Company | Power-operated loading gate for centrifugal machines incorporating an auxiliary drive device |
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US4456591A (en) | 1981-06-25 | 1984-06-26 | Baxter Travenol Laboratories, Inc. | Therapeutic method for activating factor VII |
| US4546082A (en) | 1982-06-17 | 1985-10-08 | Regents Of The Univ. Of California | E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins |
| US4599311A (en) | 1982-08-13 | 1986-07-08 | Kawasaki Glenn H | Glycolytic promotersfor regulated protein expression: protease inhibitor |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| WO1984004330A1 (en) | 1983-04-22 | 1984-11-08 | Amgen | Secretion of exogenous polypeptides from yeast |
| NZ207926A (en) | 1983-04-25 | 1988-04-29 | Genentech Inc | Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast |
| US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| US4870008A (en) | 1983-08-12 | 1989-09-26 | Chiron Corporation | Secretory expression in eukaryotes |
| US4879236A (en) | 1984-05-16 | 1989-11-07 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| US4931373A (en) | 1984-05-25 | 1990-06-05 | Zymogenetics, Inc. | Stable DNA constructs for expression of α-1 antitrypsin |
| DK58285D0 (da) | 1984-05-30 | 1985-02-08 | Novo Industri As | Peptider samt fremstilling og anvendelse deraf |
| US4766073A (en) | 1985-02-25 | 1988-08-23 | Zymogenetics Inc. | Expression of biologically active PDGF analogs in eucaryotic cells |
| US4885249A (en) | 1984-12-05 | 1989-12-05 | Allelix, Inc. | Aspergillus niger transformation system |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| GR860984B (en) | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
| NZ217373A (en) | 1985-08-29 | 1990-10-26 | Genencor Inc | Production of heterologous peptide in filamentous fungi, vectors and dna |
| JP2523562B2 (ja) | 1985-10-25 | 1996-08-14 | ザイモジェネティックス インコーポレーテッド | 外来タンパク質を分泌することを目的としたｂａｒ１の使用法 |
| US4882279A (en) | 1985-10-25 | 1989-11-21 | Phillips Petroleum Company | Site selective genomic modification of yeast of the genus pichia |
| US4935349A (en) | 1986-01-17 | 1990-06-19 | Zymogenetics, Inc. | Expression of higher eucaryotic genes in aspergillus |
| DK122686D0 (da) | 1986-03-17 | 1986-03-17 | Novo Industri As | Fremstilling af proteiner |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| GB8615942D0 (en) | 1986-06-30 | 1986-08-06 | Animal & Food Research Council | Peptide production |
| NZ221259A (en) | 1986-07-31 | 1990-05-28 | Calgene Inc | Seed specific transcriptional regulation |
| EP0832981A1 (en) | 1987-02-17 | 1998-04-01 | Pharming B.V. | DNA sequences to target proteins to the mammary gland for efficient secretion |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| ATE170557T1 (de) | 1987-07-24 | 1998-09-15 | Chiron Corp | Züchtung von insektenzellen mit airlift-reaktoren |
| US5024947A (en) | 1987-07-24 | 1991-06-18 | Cetus Corporation | Serum free media for the growth on insect cells and expression of products thereby |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| DE3886221T3 (de) | 1987-09-04 | 2000-12-21 | Novo Nordisk A/S, Bagsvaerd | VERFAHREN ZUR HERSTELLUNG VON PROTEINPRODUKTEN IN -i(ASPERGILLUS) UND PROMOTOREN ZUR VERWENDUNG IN -i(ASPERGILLUS). |
| DK463887D0 (da) | 1987-09-07 | 1987-09-07 | Novo Industri As | Gaerleader |
| US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
| GB8826446D0 (en) | 1988-11-11 | 1988-12-14 | Agricultural & Food Res | Peptide production |
| WO1990005783A1 (en) | 1988-11-18 | 1990-05-31 | Cetus Corporation | Insect signal peptide mediated secretion of recombinant proteins |
| GB8910962D0 (en) | 1989-05-12 | 1989-06-28 | Natural Environment Res | Novel baculovirus expression vectors and use thereof in the expression of foreign proteins in insects or insect cells |
| US5162222A (en) | 1989-07-07 | 1992-11-10 | Guarino Linda A | Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses |
| US5077214A (en) | 1989-07-07 | 1991-12-31 | The Texas A&M University System | Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells |
| US5155037A (en) | 1989-08-04 | 1992-10-13 | The Texas A&M University System | Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems |
| US5073964A (en) | 1989-08-04 | 1991-12-17 | Aware, Inc. | Signal processing device and method |
| US5023328A (en) | 1989-08-04 | 1991-06-11 | The Texas A&M University System | Lepidopteran AKH signal sequence |
| DK300090D0 (da) | 1990-12-19 | 1990-12-19 | Novo Nordisk As | Fremgangsmaade til fremstilling af leadersekvenser |
| CA2099562C (en) | 1991-01-11 | 2010-04-20 | William N. Drohan | Expression of active human protein c in mammary tissue of transgenic animals |
| ATE428445T1 (de) * | 2000-02-11 | 2009-05-15 | Bayer Healthcare Llc | Gerinnungsfaktor vii oder viia konjugate |
| CN100475959C (zh) * | 2000-09-13 | 2009-04-08 | 诺沃挪第克健康护理股份公司 | 人凝血因子vii变体 |
| JP2004529640A (ja) | 2001-03-22 | 2004-09-30 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 第ｖｉｉ凝固因子誘導体 |
| DK1578771T3 (da) | 2001-10-10 | 2013-06-10 | Novo Nordisk As | Remodellering og glycokonjugering af peptider |
| ES2434032T3 (es) * | 2005-06-17 | 2013-12-13 | Novo Nordisk Health Care Ag | Compuestos de FVIIA diméricos y multiméricos |
| US20090055942A1 (en) | 2005-09-14 | 2009-02-26 | Novo Nordisk Healthcare A/G | Human Coagulation Factor VII Polypeptides |
| CN101466400B (zh) | 2006-04-07 | 2014-06-25 | 诺沃-诺迪斯克保健股份有限公司 | 共价凝血因子ⅶ-组织因子复合物 |
| US9687559B2 (en) | 2008-03-19 | 2017-06-27 | The Board Of Regents Of The University Of Oklahoma | Heparosan polymers and methods of making and using same for the enhancement of therapeutics |
| TWI538916B (zh) | 2008-04-11 | 2016-06-21 | 介控生化科技公司 | 經修飾的因子vii多肽和其用途 |
| EP2341941A4 (en) * | 2008-09-09 | 2014-12-10 | Univ Oklahoma | HEPAROSANE POLYMERS AND METHODS OF MAKING AND USING THEM TO ENHANCE THERAPEUTIC COMPOUNDS |
-
2013
- 2013-10-15 US US14/675,887 patent/US20150307865A1/en not_active Abandoned
- 2013-10-15 WO PCT/EP2013/071510 patent/WO2014060401A1/en active Application Filing
- 2013-10-15 EP EP13777046.7A patent/EP2906693A1/en not_active Withdrawn
- 2013-10-15 CN CN201380053832.3A patent/CN104704118A/zh not_active Withdrawn
- 2013-10-15 JP JP2015536187A patent/JP2015532307A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015532307A5 (ja) | ||
| JP2015502991A5 (ja) | ||
| US11229678B2 (en) | Neuroprotective peptides | |
| HRP20140616T1 (hr) | Peptidni analog oksintomodulina | |
| TW201613958A (en) | MIC-1 fusion proteins and uses thereof | |
| JP2018522563A5 (ja) | ||
| JP2014526441A5 (ja) | ||
| BR112019002394A2 (pt) | citocina fundida com fc heterodimérico e composição farmacêutica compreendendo o mesmo | |
| HRP20220639T1 (hr) | Kimerni i hibridni polipeptidi faktora viii i postupci njihove upotrebe | |
| JP2011523935A5 (ja) | ||
| HRP20041108B1 (hr) | Peptidi povezani sa tumorom koji se vežu na mhc molekule | |
| AR064555A1 (es) | Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo | |
| BRPI0814097A8 (pt) | Derivado do peptídeo insulinotrópico cm seu aminoácido n-terminal modificado | |
| RU2008141280A (ru) | Агонисты рецептора нейромедина u и их применение | |
| HK1121468A1 (en) | Synthetic mecp2 sequence for protein substitution therapy | |
| JP2013533273A5 (ja) | ||
| JP2015512927A5 (ja) | ||
| WO2014140103A3 (en) | Thrombin sensitive coagulation factor x molecules | |
| JP2016536357A5 (ja) | ||
| HRP20110724T1 (hr) | Smjese koje sadrže peptide mijelinskog bazičnog proteina i njihova medicinska uporaba | |
| JP2009533355A5 (ja) | ||
| JP2013531651A5 (ja) | ||
| JP2016520620A5 (ja) | ||
| WO2016122806A8 (en) | Compositions and methods of using a soluble tnf-alpha receptor modified for increased half-life | |
| US20200172587A1 (en) | Hydrochloride salts of c5a receptor agonist peptides |